Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

被引：0
|
作者：
Margaret P. Staples
Lyn March
Catherine Hill
Marissa Lassere
Rachelle Buchbinder
机构：
[1] Cabrini Institute,Monash Department of Clinical Epidemiology
[2] Monash University,Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine
[3] Royal North Shore Hospital,Florance and Cope Professorial Department of Rheumatology
[4] Institute of Bone and Joint Research,Discipline of Medicine
[5] University of Sydney,undefined
[6] The Queen Elizabeth and Royal Adelaide Hospitals,undefined
[7] University of Adelaide,undefined
[8] St George Hospital,undefined
[9] University of New South Wales,undefined
来源：
BMC Rheumatology | / 3卷
关键词：
Rheumatoid arthritis; Malignancy; Tumour necrosis factor; Biologic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 44 条
  • [31] Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
    Kopp, Tine Iskov
    Delcoigne, Benedicte
    Arkema, Elizabeth V.
    Jacobsen, Rikke Kart
    Magyari, Melinda
    Ibfelt, Else Helene
    Locht, Henning
    Sellebjerg, Finn
    Cordtz, Rene Lindholm
    Jensen, Dorte V.
    Askling, Johan
    Dreyer, Lene
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (05) : 566 - 572
  • [32] Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study
    Inciarte-Mundo, Jose
    Ramirez, Julio
    Victoria Hernandez, Maria
    Ruiz-Esquide, Virginia
    Cuervo, Andrea
    Raquel Cabrera-Villalba, Sonia
    Pascal, Mariona
    Yague, Jordi
    Canete, Juan D.
    Sanmarti, Raimon
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [33] Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study
    José Inciarte-Mundo
    Julio Ramirez
    Maria Victoria Hernández
    Virginia Ruiz-Esquide
    Andrea Cuervo
    Sonia Raquel Cabrera-Villalba
    Mariona Pascal
    Jordi Yagüe
    Juan D. Cañete
    Raimon Sanmarti
    Arthritis Research & Therapy, 20
  • [34] Periodontitis and Etanercept Discontinuation Risk in Anti-Tumor Necrosis Factor-Naive Rheumatoid Arthritis Patients A Nationwide Population-Based Cohort Study
    Chen, Hsin-Hua
    Chen, Der-Yuan
    Lai, Kuo-Lung
    Chen, Yi-Ming
    Chou, Yiing-Jenq
    Chou, Pesus
    Lin, Ching-Heng
    Huang, Nicole
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2013, 19 (08) : 432 - 438
  • [35] The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database
    Sakai, Ryoko
    Cho, Soo-Kyung
    Nanki, Toshihiro
    Koike, Ryuji
    Watanabe, Kaori
    Yamazaki, Hayato
    Nagasawa, Hayato
    Amano, Koichi
    Tanaka, Yoshiya
    Sumida, Takayuki
    Ihata, Atsushi
    Yasuda, Shinsuke
    Nakajima, Atsuo
    Sugihara, Takahiko
    Tamura, Naoto
    Fujii, Takao
    Dobashi, Hiroaki
    Miura, Yasushi
    Miyasaka, Nobuyuki
    Harigai, Masayoshi
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (12) : 1729 - 1736
  • [36] The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database
    Ryoko Sakai
    Soo-Kyung Cho
    Toshihiro Nanki
    Ryuji Koike
    Kaori Watanabe
    Hayato Yamazaki
    Hayato Nagasawa
    Koichi Amano
    Yoshiya Tanaka
    Takayuki Sumida
    Atsushi Ihata
    Shinsuke Yasuda
    Atsuo Nakajima
    Takahiko Sugihara
    Naoto Tamura
    Takao Fujii
    Hiroaki Dobashi
    Yasushi Miura
    Nobuyuki Miyasaka
    Masayoshi Harigai
    Rheumatology International, 2014, 34 : 1729 - 1736
  • [37] EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden
    Gulfe, Anders
    Wallman, Johan K.
    Kristensen, Lars Erik
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [38] EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden
    Anders Gülfe
    Johan K. Wallman
    Lars Erik Kristensen
    Arthritis Research & Therapy, 18
  • [39] IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study
    Juhl, Pernille
    Thudium, Christian Schneider
    Gudmann, Natasja Staehr
    Karsdal, Morten Asser
    Bay-Jensen, Anne-Christine
    Siebuhr, Anne Sofie
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 568 - 574
  • [40] Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study
    Talotta, R.
    Berzi, A.
    Atzeni, F.
    Dell'Acqua, D.
    Puttini, P. Sarzi
    Trabattoni, D.
    REUMATISMO, 2016, 68 (02) : 83 - 89
12345